Filtered By:
Therapy: Statin Therapy
Countries: China Health

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 86 results found since Jan 2013.

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Stenting for Symptomatic Intracranial Vertebrobasilar Artery Stenosis in Northeast of China: A Single-Center Study
Conclusion: A high technical success rate of IVBS stenting could be achieved, and the safety was acceptable, whereas Mori C lesions were more vulnerable to endovascular procedure and showed a higher rate of complications than A and B types.
Source: Frontiers in Neurology - February 16, 2021 Category: Neurology Source Type: research

Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
CONCLUSION: Chinese patients with AF and coronary stenting had high mortality and incidence of MACCE. We compiled separate predictive models for all-cause death, IS/STE, MACCE, and major bleeding.PMID:34353224 | DOI:10.1080/00015385.2021.1950367
Source: Acta Cardiologica - August 6, 2021 Category: Cardiology Authors: Jian-Yong Zheng Yi Cao Dong-Tao Li Yi-Gang Qiu Li Zhao Zheng-Ming Xu Yi-Xiong Huang Zhi-Bo Hong Tian-Chang Li Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yu Chen Source Type: research

Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis
Conclusions: Current cigarette smoking, diabetes mellitus, and hypertension are independently associated with incident ASCVD over 16-year follow-up among those with CAC=0. Family history of premature ASCVD may be associated with ASCVD risk among women only.PMID:34879218 | DOI:10.1161/CIRCULATIONAHA.121.056705
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mahmoud Al Rifai Michael J Blaha Vijay Nambi Steven J C Shea Erin D Michos Roger S Blumenthal Christie M Ballantyne Moyses Szklo Philip Greenland Michael D Miedema Khurram Nasir Jerome I Rotter Xiuqing Guo Jie Yao Wendy S Post Salim S Virani Source Type: research

Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5million people
Conclusions: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension.
Source: International Journal of Cardiology - January 23, 2014 Category: Cardiology Authors: Yiping Chen, Liming Li, Qiuli Zhang, Robert Clarke, Junshi Chen, Yu Guo, Zheng Bian, Xianhai Pan, Richard Peto, Ran Tao, Kunxiang Shi, Rory Collins, Liangcai Ma, Huarong Sun, Zhengming Chen, on behalf of China Kadoorie Biobank Study Tags: Original Articles Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of the C-117 Formula for Vulnerable Carotid Artery Plaques (Spchim): A Randomized Double-Blind Controlled Pilot Study.
Conclusion: The C-117 formula may be antiatherosclerotic by strengthening statins to reduce the low-density lipoprotein levels and reducing the carotid plaque Crouse scores. Clinical trials with large sample sizes, long-term interventions, and follow-up are needed to investigate the efficacy of the C-117 formula. Clinical Trials Registration: This trial is registered with clinicaltrials.gov identifier: NCT03072225 (registered retrospectively on 1st March 2017). PMID: 31391862 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - August 9, 2019 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis
This study also provided evidence of biomarkers involved in hemorrhage stroke and improved understanding of the effects of HMG-COA reductase inhibition on vascular permeability and cerebral hemorrhage.
Source: Frontiers in Pharmacology - October 1, 2020 Category: Drugs & Pharmacology Source Type: research

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.
CONCLUSIONS: As an add-on to OMT, MUSKARDIA is safe and significantly reduces angina frequency in patients with stable CAD. Moreover, the use of MUSKARDIA is associated with a trend toward reduced MACEs in patients with stable CAD. The results suggest that MUSKARDIA can be used to manage patients with CAD. TRIAL REGISTRATION: No. ChiCTR-TRC-12003513. PMID: 33273369 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - December 2, 2020 Category: General Medicine Authors: Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, Zhao YL, Qian J, Jin YZ, Liu YW, Wang SH, He SH, Yang P, Wu J, Lu F, Hou ZS Tags: Chin Med J (Engl) Source Type: research